403 related articles for article (PubMed ID: 20350048)
1. Therapeutic potential of IL-27 in systemic lupus erythematosus.
Pan HF; Tao JH; Ye DQ
Expert Opin Ther Targets; 2010 May; 14(5):479-84. PubMed ID: 20350048
[TBL] [Abstract][Full Text] [Related]
2. IL-23: a promising therapeutic target for systemic lupus erythematosus.
Leng RX; Pan HF; Chen GM; Wang C; Qin WZ; Chen LL; Tao JH; Ye DQ
Arch Med Res; 2010 Apr; 41(3):221-5. PubMed ID: 20682181
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-17-producing T cells in lupus.
Crispín JC; Tsokos GC
Curr Opin Rheumatol; 2010 Sep; 22(5):499-503. PubMed ID: 20592603
[TBL] [Abstract][Full Text] [Related]
4. [Cytokines in systemic lupus erythematosus].
Robak E; Sysa-Jedrzejowska A; Robak T
Przegl Lek; 1996; 53(8):623-6. PubMed ID: 8999465
[TBL] [Abstract][Full Text] [Related]
5. New treatments for SLE: cell-depleting and anti-cytokine therapies.
Anolik JH; Aringer M
Best Pract Res Clin Rheumatol; 2005 Oct; 19(5):859-78. PubMed ID: 16150407
[TBL] [Abstract][Full Text] [Related]
6. The role of interleukin-17 in mediating joint destruction in rheumatoid arthritis.
Li X; Yuan FL; Lu WG; Zhao YQ; Li CW; Li JP; Xu RS
Biochem Biophys Res Commun; 2010 Jun; 397(2):131-5. PubMed ID: 20513356
[TBL] [Abstract][Full Text] [Related]
7. IL-17 and the Th17 lineage in systemic lupus erythematosus.
Garrett-Sinha LA; John S; Gaffen SL
Curr Opin Rheumatol; 2008 Sep; 20(5):519-25. PubMed ID: 18698171
[TBL] [Abstract][Full Text] [Related]
8. [Interleukin 10 in disseminated lupus erythematosus].
Emilie D
J Soc Biol; 2002; 196(1):19-21. PubMed ID: 12134628
[TBL] [Abstract][Full Text] [Related]
9. IL-4Ralpha polymorphism in regulation of IL-4 synthesis by T cells: implication in susceptibility to a subset of murine lupus.
Shiroiwa W; Tsukamoto K; Ohtsuji M; Lin Q; Ida A; Kodera S; Ohtsuji N; Nakamura K; Tsurui H; Kinoshita K; Nishimura H; Shirai T; Hirose S
Int Immunol; 2007 Feb; 19(2):175-83. PubMed ID: 17189592
[TBL] [Abstract][Full Text] [Related]
10. IL-18 activity in systemic lupus erythematosus.
Favilli F; Anzilotti C; Martinelli L; Quattroni P; De Martino S; Pratesi F; Neumann D; Beermann S; Novick D; Dinarello CA; Boraschi D; Migliorini P
Ann N Y Acad Sci; 2009 Sep; 1173():301-9. PubMed ID: 19758166
[TBL] [Abstract][Full Text] [Related]
11. Cytokine manipulation by methotrexate treatment in murine experimental systemic lupus erythematosus.
Dayan M; Segal R; Mozes E
J Rheumatol; 1997 Jun; 24(6):1075-82. PubMed ID: 9195512
[TBL] [Abstract][Full Text] [Related]
12. IL-33: a promising therapeutic target for rheumatoid arthritis?
Yuan FL; Li X; Lu WG; Li CW; Xu RS; Dong J
Expert Opin Ther Targets; 2011 May; 15(5):529-34. PubMed ID: 21446881
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-17 in systemic lupus erythematosus: A comprehensive review.
Li D; Guo B; Wu H; Tan L; Chang C; Lu Q
Autoimmunity; 2015; 48(6):353-61. PubMed ID: 25894789
[TBL] [Abstract][Full Text] [Related]
14. T helper cell subsets in the pathogenesis of systemic lupus erythematosus.
Reininger L; Santiago ML; Takahashi S; Fossati L; Izui S
Ann Med Interne (Paris); 1996; 147(7):467-71. PubMed ID: 9092356
[TBL] [Abstract][Full Text] [Related]
15. 'Not only...but also': factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus.
Bruce IN
Rheumatology (Oxford); 2005 Dec; 44(12):1492-502. PubMed ID: 16234277
[TBL] [Abstract][Full Text] [Related]
16. Hormones and lupus: defective dehydroepiandrosterone activity induces impaired interleukin-2 activity of T lymphocytes in patients with systemic lupus erythematosus.
Suzuki N; Suzuki T; Sakane T
Ann Med Interne (Paris); 1996; 147(4):248-52. PubMed ID: 8952743
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of (S)-armepavine from Nelumbo nucifera on autoimmune disease of MRL/MpJ-lpr/lpr mice.
Liu CP; Tsai WJ; Shen CC; Lin YL; Liao JF; Chen CF; Kuo YC
Eur J Pharmacol; 2006 Feb; 531(1-3):270-9. PubMed ID: 16413531
[TBL] [Abstract][Full Text] [Related]
18. Prostaglandin E2-mediated dysregulation of proinflammatory cytokine production in pristane-induced lupus mice.
Chae BS; Shin TY; Kim DK; Eun JS; Leem JY; Yang JH
Arch Pharm Res; 2008 Apr; 31(4):503-10. PubMed ID: 18449509
[TBL] [Abstract][Full Text] [Related]
19. Interleukin 2 and systemic lupus erythematosus: beyond the transcriptional regulatory net abnormalities.
Gómez-Martín D; Díaz-Zamudio M; Crispín JC; Alcocer-Varela J
Autoimmun Rev; 2009 Sep; 9(1):34-9. PubMed ID: 19269352
[TBL] [Abstract][Full Text] [Related]
20. Type-I interferons and systemic lupus erythematosus.
Koutouzov S; Mathian A; Dalloul A
Autoimmun Rev; 2006 Oct; 5(8):554-62. PubMed ID: 17027892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
